Pharmaceutical Industry Today
Global Human Insulin Market Will Reach US$49 billion in 2020, Research Report by PMR
North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market.
Published 06 August 2015
New York: According to a new market report published by Persistence Market Research “Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020,” the global human insulin market was valued at USD 24,332.6 million in 2014 and was expected to grow at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of USD 49,197.3 million in 2020.
Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and increasing awareness among people about diabetes care. In addition, technological advancements in insulin delivery devices and increasing the prevalence of lifestyle related disorders such as obesity are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries such as Brazil, India, and China are inhibiting the growth of the human insulin market. In addition, strict regulatory requirements for drug approval are also restraining the growth of the market. The global human insulin market was anticipated to grow from an estimated USD 24,332.6 million in 2014 to USD 49,197.3 million in 2020 at a CAGR of 12.4% during the forecast period.
Browse the full report at: http://www.persistencemarketresearch.com/market-research/human-insulin-market.asp
In North America, increasing the prevalence of diabetes with growing age and availability of advanced human insulin infusion devices are driving the use of human insulin in the market.
In addition, increasing the prevalence of lifestyle associated disorders such as obesity is also boosting the growth of the human insulin market in this region. For instance, according to the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health institute, over one-third children and adolescents were obese in 2012 in the U.S.
In Europe, the human insulin market is driven by rising aging population and increasing prevalence of diabetes. In addition, in Germany the market is evolving due to rising prevalence of diabetes and increasing awareness among people about diabetes care. However, in Asia-Pacific the growth for human insulin is much higher than developed countries due to increasing prevalence of diabetes and increasing government initiatives for improving healthcare.
Request Sample Report: http://www.persistencemarketresearch.com/samples/3308
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc and Oramed Pharmaceuticals, Inc. are some of the major players in human insulin market.
The human insulin market is segmented as follows:
Human insulin market, by type
- Traditional human insulin
- Modern human insulin
Traditional human insulin market, by type
- Short-acting human insulin
- Intermediate-acting human insulin
- Premixed human insulin
Modern human insulin market, by type
- Rapid-acting human insulin
- Long-acting human insulin
- Premixed human insulin
Human insulin market, by disease
- Type 1 diabetes
- Type 2 diabetes
Traditional human insulin market, by brand
- Humulin
- Insuman
- Others
Modern human insulin market, by brand
- Lantus
- Novolog
- Humalog
- Levemir
- Novomix
- Apidra
- Others
Human insulin market, by geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- The U.K.
- Asia-Pacific
- Japan
- China
- India
- Rest of the World (RoW)
Contact
Addie Thomas
305 Broadway
7th Floor
New York City, NY 10007
United States
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
